Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 2/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.34 |
| ▸ | CPA3 | P15088 | 1/20 | 0.33 |
| ▸ | BMP1 | P13497 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16812537 | 0.82 | MCL1 (0.40) | FOLH1CPB2CPA3 | |
| SCHEMBL23179898 | 0.77 | ALDH1A1 (0.38) | FOLH1SMN1; SMN2ALDH1A1 | |
| SCHEMBL26740183 | 0.76 | MME (0.48) | FOLH1MAPTBLMMMEACE | |
| SCHEMBL27369997 | 0.75 | ALDH1A1 (0.33) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL15071678 | 0.74 | SMN1; SMN2 (0.50) | KDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL23805305 | 0.72 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL27266013 | 0.71 | ALDH1A1 (0.34) | FOLH1SMN1; SMN2ALDH1A1 | |
| SCHEMBL26818226 | 0.71 | ALDH1A1 (0.39) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL26831486 | 0.69 | ALDH1A1 (0.38) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL15604525 | 0.69 | ECE1 (0.47) | MMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338555-A1 | CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | IONIS PHARMACEUTICALS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230338555-A1 | CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | DCLRE1B, RNASE1, LNPEP | FOLH1 34/4885KDM4E 4388/4885MAPT 3113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.